Eli Lilly and the WHO Foundation have partnered to support the World Health Organization’s (WHO) global action plan on the public response to dementia.
Established in 2020, the WHO Foundation is an independent organisation that mobilises philanthropic investment and fosters collaborations between public and private sectors to address global health challenges and advance health equity. Under the new agreement, Lilly will provide financial support to the Foundation to strengthen the implementation of the WHO’s dementia strategy.
Anil Soni, WHO Foundation CEO said: “Too many people around the world are living with dementia without a diagnosis, without access to quality care, and without the support they and their caregivers need. This partnership will provide much-needed resources for WHO to work with countries to improve the experiences of people living with dementia and those who care for them.”
Dementia is the seventh leading cause of death globally and a major contributor to disability and dependency among older adults. As of 2021, an estimated 57 million people worldwide were living with dementia, with more than 60% residing in low- and middle-income countries.
Member States at the United Nations General Assembly on the prevention and control of noncommunicable diseases and the promotion of mental health and well-being have recognised dementia and Alzheimer’s disease – the most common form of dementia – as public health priorities.
Key priorities of the partnership include enhancing risk reduction strategies, improving early detection and diagnosis, and raising standards of care.
Patrik Jonsson, executive vice president and president of Lilly International said: “For over 35 years, Lilly has been driving scientific progress to improve the diagnostics, treatments, and outcomes for people with Alzheimer’s disease. Today, we are at a pivotal time in the fight against Alzheimer’s disease as our understanding of disease pathology unlock innovative solutions.”
“However, healthcare systems around the world remain unprepared to deliver these innovations. Detecting and treating Alzheimer’s disease early is crucial, as pathological changes begin years before symptoms appear. Diagnosing the disease at this earliest stage provides answers to patients and caregivers sooner, empowering them to make informed choices. Our collaboration with the WHO Foundation aims to support WHO to close critical gaps to ensure that those affected by this disease have access to the care, support and solutions they need.”